Literature DB >> 8632325

Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.

A H Lichtman1, S A Cook, B R Martin.   

Abstract

The purpose of this study was to elucidate brain areas that mediate cannabinoid-induced antinociception as assessed in the tail-flick test. Intracerebroventricular administration of the prototypical cannabinoid, delta 9-tetrahydrocannabinol, and the potent bicyclic analog, CP-55,940, produced antinociception at ED50 values of 373 and 64 nmol/rat, respectively. Hypothermic and cataleptic effects also were observed after i.c.v. administration of CP-55,940, but not delta 9-tetrahydrocannabinol. In contrast, the endogenous cannabinoid, anandamide, failed to elicit any apparent pharmacological effects. Administration of CP-55,940 into the caudate putamen produced catalepsy, but failed to produce either antinociception or hypothermia. Micro-injection of CP-55,940 into the ventrolateral aspect of the periaqueductal gray (PAG), in the region of the dorsal raphe, produced antinociception (ED50 dose = 28 nmol/rat), catalepsy and hypothermia. CP-56,667, the inactive stereoisomer of CP-55,940, failed to produce any effects when injected into the same site. Additional studies demonstrated that pertussis toxin completely prevented the pharmacological effects of CP-55,940 when both agents were administered into the posterior ventrolateral PAG. In contrast, dibutyryl-cAMP failed to attenuate cannabinoid-induced antinociception. Finally, CP-55,940 administered into either the posterior dorsolateral or the anterior ventrolateral areas of the PAG was without effect. These results indicate that the antinociceptive and cataleptic effects of cannabinoids in the PAG are dose-related, exhibit regional specificity and are enantioselective. Moreover, the complete prevention of these pharmacological effects by pertussis toxin pretreatment in the PAG is consistent with the involvement of G proteins. These findings suggest that the posterior ventrolateral PAG may be an important brain area for the antinociceptive and cataleptic effects of the cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632325

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  74 in total

1.  Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro.

Authors:  C W Vaughan; I S McGregor; M J Christie
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.

Authors:  Pattipati S Naidu; Steven G Kinsey; Tai L Guo; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

3.  Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.

Authors:  Shao M Tham; James A Angus; Elizabeth M Tudor; Christine E Wright
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

4.  Upregulation of fatty acid amide hydrolase in the dorsal periaqueductal gray is associated with neuropathic pain and reduced heart rate in rats.

Authors:  Caron Dean; Cecilia J Hillard; Jeanne L Seagard; Francis A Hopp; Quinn H Hogan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-02-01       Impact factor: 3.619

5.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

6.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

7.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

8.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Role of endogenous sleep-wake and analgesic systems in anesthesia.

Authors:  Jun Lu; Laura E Nelson; Nick Franks; Mervyn Maze; Nancy L Chamberlin; Clifford B Saper
Journal:  J Comp Neurol       Date:  2008-06-01       Impact factor: 3.215

Review 10.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.